RYTM Long Put Strategy

RYTM (Rhythm Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome.

RYTM (Rhythm Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $7.53B, a beta of 1.92 versus the broader market, a 52-week range of 62.29-122.2, average daily share volume of 815K, a public-listing history dating back to 2017, approximately 283 full-time employees. These structural characteristics shape how RYTM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.92 indicates RYTM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long put on RYTM?

A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.

Current RYTM snapshot

As of June 30, 2026, spot at $112.30, ATM IV 51.30%, IV rank 13.22%, expected move 14.71%. The long put on RYTM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this long put structure on RYTM specifically: RYTM IV at 51.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a RYTM long put, with a market-implied 1-standard-deviation move of approximately 14.71% (roughly $16.52 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RYTM expiries trade a higher absolute premium for lower per-day decay. Position sizing on RYTM should anchor to the underlying notional of $112.30 per share and to the trader's directional view on RYTM stock.

RYTM long put setup

The RYTM long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RYTM near $112.30, the first option leg uses a $110.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RYTM chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RYTM shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Put$110.00$3.95

RYTM long put risk and reward

Net Premium / Debit
-$395.00
Max Profit (per contract)
$10,604.00
Max Loss (per contract)
-$395.00
Breakeven(s)
$106.05
Risk / Reward Ratio
26.846

Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.

RYTM long put payoff curve

Modeled P&L at expiration across a range of underlying prices for the long put on RYTM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

RYTM long put profit and loss curve at expiration with breakevens and current spot markedRYTM long put payoff at expiration$0$2000$4000$6000$8000$10000$50$100$150$200Underlying Price ($)P&L at Expiration ($)BE $106.05Spot $112.30
P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.
Underlying Price% From SpotP&L at Expiration
$0.01-100.0%+$10,604.00
$24.84-77.9%+$8,121.10
$49.67-55.8%+$5,638.19
$74.50-33.7%+$3,155.29
$99.33-11.6%+$672.38
$124.16+10.6%-$395.00
$148.98+32.7%-$395.00
$173.81+54.8%-$395.00
$198.64+76.9%-$395.00
$223.47+99.0%-$395.00

When traders use long put on RYTM

Long puts on RYTM hedge an existing long RYTM stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying RYTM exposure being hedged.

RYTM thesis for this long put

The market-implied 1-standard-deviation range for RYTM extends from approximately $95.78 on the downside to $128.82 on the upside. A RYTM long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long RYTM position with one put per 100 shares held. Current RYTM IV rank near 13.22% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RYTM at 51.30%. As a Healthcare name, RYTM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RYTM-specific events.

RYTM long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RYTM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RYTM alongside the broader basket even when RYTM-specific fundamentals are unchanged. Long-premium structures like a long put on RYTM are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RYTM chain quotes before placing a trade.

Frequently asked questions

What is a long put on RYTM?
A long put on RYTM is the long put strategy applied to RYTM (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With RYTM stock trading near $112.30, the strikes shown on this page are snapped to the nearest listed RYTM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are RYTM long put max profit and max loss calculated?
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the RYTM long put priced from the end-of-day chain at a 30-day expiry (ATM IV 51.30%), the computed maximum profit is $10,604.00 per contract and the computed maximum loss is -$395.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RYTM long put?
The breakeven for the RYTM long put priced on this page is roughly $106.05 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RYTM market-implied 1-standard-deviation expected move is approximately 14.71%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long put on RYTM?
Long puts on RYTM hedge an existing long RYTM stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying RYTM exposure being hedged.
How does current RYTM implied volatility affect this long put?
RYTM ATM IV is at 51.30% with IV rank near 13.22%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related RYTM analysis